Key facts
- ABLi Therapeutics’s last known valuation is $95.0M.
- It has raised $26.0M across 1 recorded rounds; the latest was Seed Round ($1.0M) in Sep 2025.
- Notable investors include U.S. Department of Health and Human Services.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for ABLi Therapeutics
Funding rounds
1 roundsAbout ABLi Therapeutics
Developer of small molecule therapeutics designed to target the underlying causes of diseases driven by activation or dysfunction of the Abelson Tyrosine Kinases (c-Abl). The company offers brain-penetrant, potent, and selective kinase inhibitors with improved safety and disease-modifying potential, enabling patients with Parkinson's disease and related neurodegenerative disorders to achieve better clinical outcomes and slowed disease progression.
- Sector
- Healthcare
- HQ
- Atlanta, GA, United States
- Employees
- 5
- Website
- ablitherapeutics.com/
- Ownership
- Privately Held (backing)
ABLi Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ABLi Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ABLi Therapeutics in its N-PORT filings yet. We sweep new filings monthly.